Found: 185
Select item for more details and to access through your institution.
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS Program.
- Published in:
- Diabetologia, 2021, v. 64, n. 11, p. 2402, doi. 10.1007/s00125-021-05524-1
- By:
- Publication type:
- Article
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 10, p. 2147, doi. 10.1007/s00125-021-05512-5
- By:
- Publication type:
- Article
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
- Published in:
- Diabetologia, 2019, v. 62, n. 10, p. 1854, doi. 10.1007/s00125-019-4955-5
- By:
- Publication type:
- Article
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
- Published in:
- Diabetologia, 2019, v. 62, n. 6, p. 926, doi. 10.1007/s00125-019-4839-8
- By:
- Publication type:
- Article
Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP).
- Published in:
- NPJ Digital Medicine, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s41746-022-00622-9
- By:
- Publication type:
- Article
Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure.
- Published in:
- ESC Heart Failure, 2020, v. 7, n. 1, p. 274, doi. 10.1002/ehf2.12528
- By:
- Publication type:
- Article
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 93, doi. 10.1007/s40256-021-00491-9
- By:
- Publication type:
- Article
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II).
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 5, p. 553, doi. 10.1007/s40256-021-00473-x
- By:
- Publication type:
- Article
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3530, doi. 10.1111/dom.15685
- By:
- Publication type:
- Article
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3371, doi. 10.1111/dom.15678
- By:
- Publication type:
- Article
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 758, doi. 10.1111/dom.15340
- By:
- Publication type:
- Article
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091
- By:
- Publication type:
- Article
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2043, doi. 10.1111/dom.15065
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2038, doi. 10.1111/dom.15057
- By:
- Publication type:
- Article
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1413, doi. 10.1111/dom.14978
- By:
- Publication type:
- Article
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2459, doi. 10.1111/dom.14832
- By:
- Publication type:
- Article
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1927, doi. 10.1111/dom.14772
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1072, doi. 10.1111/dom.14671
- By:
- Publication type:
- Article
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 12, doi. 10.1111/dom.14539
- By:
- Publication type:
- Article
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2707, doi. 10.1111/dom.14525
- By:
- Publication type:
- Article
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1652, doi. 10.1111/dom.14386
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 382, doi. 10.1111/dom.14226
- By:
- Publication type:
- Article
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2199, doi. 10.1111/dom.14143
- By:
- Publication type:
- Article
Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, p. 46, doi. 10.1111/dom.13987
- By:
- Publication type:
- Article
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 530, doi. 10.1111/dom.13920
- By:
- Publication type:
- Article
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 926, doi. 10.1111/dom.12924
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal ( CANVAS-R): A randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 387, doi. 10.1111/dom.12829
- By:
- Publication type:
- Article
Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 16, p. 1903, doi. 10.1001/jama.299.16.1903
- By:
- Publication type:
- Article
Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions.
- Published in:
- 2007
- By:
- Publication type:
- commentary
Optimal Timing for Use of Glycoprotein llb/llla Inhibitors in Acute Coronary Syndromes.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
- Published in:
- JAMA: Journal of the American Medical Association, 2007, v. 297, n. 1, p. 43, doi. 10.1001/jama.297.1.43
- By:
- Publication type:
- Article
Low-Molecular-Weight Heparin vs Unfractionated Heparin in Acute Coronary Syndromes.
- Published in:
- 2006
- By:
- Publication type:
- Letter
High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin: Outcomes at 6 Months and 1 Year in the SYNERGY Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2005, v. 294, n. 20, p. 2594, doi. 10.1001/jama.294.20.2594
- By:
- Publication type:
- Article
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non--ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy.
- Published in:
- JAMA: Journal of the American Medical Association, 2004, v. 292, n. 1, p. 45
- By:
- Publication type:
- Article
Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non--ST-Segment Elevation Acute Coronary Syndromes.
- Published in:
- JAMA: Journal of the American Medical Association, 2004, v. 292, n. 1, p. 89, doi. 10.1001/jama.292.1.89
- By:
- Publication type:
- Article
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2022, v. 27, n. 1, p. 21, doi. 10.1177/1358863X211038620
- By:
- Publication type:
- Article
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2021, v. 26, n. 6, p. 608, doi. 10.1177/1358863X211017641
- By:
- Publication type:
- Article
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
- Published in:
- Vascular Medicine, 2019, v. 24, n. 5, p. 422, doi. 10.1177/1358863X19864172
- By:
- Publication type:
- Article
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
- Published in:
- Vascular Medicine, 2018, v. 23, n. 6, p. 523, doi. 10.1177/1358863X18775594
- By:
- Publication type:
- Article
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
- Published in:
- Pharmaceutical Statistics, 2015, v. 14, n. 4, p. 368, doi. 10.1002/pst.1694
- By:
- Publication type:
- Article
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
- Published in:
- Pharmaceutical Statistics, 2015, v. 14, n. 3, p. 242, doi. 10.1002/pst.1680
- By:
- Publication type:
- Article
Reviewing the role of healthy volunteer studies in drug development.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01832-5
- By:
- Publication type:
- Article
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.
- Published in:
- EP: Europace, 2016, v. 18, n. 8, p. 1135, doi. 10.1093/europace/euv404
- By:
- Publication type:
- Article
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials: A Systematic Review.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 4, p. e248818, doi. 10.1001/jamanetworkopen.2024.8818
- By:
- Publication type:
- Article
4243 Developing clinical research units to improve quality, efficiency, and cost effectiveness within an academic institution.
- Published in:
- 2020
- By:
- Publication type:
- Abstract
The development of a mobile app‐focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials.
- Published in:
- Stat, 2022, v. 11, n. 1, p. 1, doi. 10.1002/sta4.470
- By:
- Publication type:
- Article